Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth

Hansen, Wiebke; Hutzler, Marina; Abel, Simone; Alter, Christina; Stockmann, Christian; Kliche, Stefanie; Albert, Juliane; Sparwasser, Tim; Sakaguchi, Shimon; Westendorf, Astrid M.; Schadendorf, Dirk; Buer, Jan; Helfrich, Iris

doi:10.1084/jem.20111497

Cited by 212 publications

(200 citation statements)

References 56 publications

(84 reference statements)

Supporting

Mentioning

193

Contrasting

Order By: Relevance

“…Secretion of the CCL21 chemokine by melanoma cells and the consequent induction of a lymphoid stromal network by this chemokine also promotes accumulation of FoxP3 þ Tregs that is associated with robust tumor growth (66). Tumor-derived VEGF can also contribute to the recruitment of FoxP3 þ Tregs via an interaction with neuropilin-1, which is highly expressed by at least some Tregs (60,67). These findings suggest that the antitumor effects observed in some studies of anti-VEGF might reflect, in part, reduced recruitment of FoxP3 þ CD4 Tregs (68,69).…”

Section: Follicular Helper T Cells the Definition Of Follicular Helpementioning

confidence: 99%

CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful

Kim

Cantor²

2014

Cancer Immunology Research

287

260

View full text Add to dashboard Cite

Research over the past decade has revealed the increasingly complex biologic features of the CD4 þ T-cell lineage. This T-cell subset, which was originally defined on the basis of helper activity in antibody responses, expresses receptors that recognize peptides that have been processed and presented by specialized antigenpresenting cells. At the core of the adaptive immune response, CD4 T cells display a large degree of plasticity and the ability to differentiate into multiple sublineages in response to developmental and environmental cues. These differentiated sublineages can orchestrate a broad range of effector activities during the initiation, expansion, and memory phase of an immune response. The contribution of CD4 cells to host defense against pathogenic invasion and regulation of autoimmunity is now well established. Emerging evidence suggests that CD4 cells also actively participate in shaping antitumor immunity. Here, we outline the biologic properties of CD4 T-cell subsets with an emphasis on their contribution to the antitumor response. Cancer Immunol Res; 2(2); 91-98. Ó2014 AACR.

show abstract

Section: Follicular Helper T Cells the Definition Of Follicular Helpementioning

confidence: 99%

CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful

Kim

Cantor²

2014

Cancer Immunology Research

287

260

View full text Add to dashboard Cite

show abstract

“…Apart from its role in angiogenesis, VEGF is reported to have an influence on the recruitment of immune cells in the tumor microenvironment thereby altering the host response to tumor, such as inducing an immunosuppressive microenvironment [90]. In the case of MPM, in addition to acting as an endothelial cell mitogen triggering angiogenesis and tumor growth [91], VEGF can function as a vascular permeability enhancer contributing to the production of pleural effusion [92,93].…”

Section: Vegfmentioning

confidence: 99%

Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma

Liu

Jiao

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a highly aggressive tumor of the pleura closely related to asbestos exposure. Rare as it is, the incidence of MPM is predicted to increase mainly as a result of a lengthy latency period from the initial asbestos exposure, making it a public health concern for the next decades. Moreover, the patients with MPM have an extremely poor prognosis due to its high resistance to conventional oncologic treatments and delayed diagnosis. Although the result of current therapeutic modalities based on patient features and clinical stages is very frustrating, great advances have been shown in the knowledge of molecular biology of MPM in recent years. This is accompanied by dozens of putative prognostic biomarkers that are actively involved in tumor biological activities. These prognostic candidates can offer us a new insight into the biological characteristics of MPM, contributing to development of individualized therapeutic strategies directed against oncogenesis and tumor progression. Thus, personalized approaches based on the molecular biology of the patient's tissue or body fluid will potentially improve the present disappointing outcome, bringing new hope for patients with MPM. This article reviews the principal and several novel biomarkers that can have an influence on prognosis, in the hope that they can provide us with a more profound understanding of the biology of this lethal disease.

show abstract

“…Other microenvironmental components, such as hypoxia and hypoxia-induced VEGF, affect tumor and immune cell plasticity by recruitment of regulatory T cells and other immune suppressive immune cells contributing to an angiogenic switch [52,53]. A side effect of hypoxia, altered tumor metabolism and tumor acidification via lactate secretion and anaerobic glycolysis results in an impaired immune effector T cell function [53] and enhanced recruitment of myeloid derived suppressor cells, further promoting tumor aggressiveness and therapy resistance via microenvironmentally induced tumor plasticity.…”

Section: Inflammatory Microenvironment: Inflammatory Mediators Inducementioning

confidence: 99%

“…A side effect of hypoxia, altered tumor metabolism and tumor acidification via lactate secretion and anaerobic glycolysis results in an impaired immune effector T cell function [53] and enhanced recruitment of myeloid derived suppressor cells, further promoting tumor aggressiveness and therapy resistance via microenvironmentally induced tumor plasticity.…”

Section: Inflammatory Microenvironment: Inflammatory Mediators Inducementioning

confidence: 99%

Tumor cell plasticity: the challenge to catch a moving target

Schwitalla

2014

J Gastroenterol

View full text Add to dashboard Cite

Every cancer cell is ''different''-within one and the same tumor, between different lesions originating from the same tumor, among different patients suffering from the same tumor type, and certainly between different tumor types. The complexity of tumor development, with its genetic, phenotypic and functional heterogeneity and plasticity within tumors and between primary tumors and metastases, underlies the unpredictable influences and stimuli of a tumor-associated inflammatory microenvironment, immune response, mechanical and metabolic stress, therapy-induced inflammation or interaction with microbiota. The stochastic and context dependent nature of these factors accounts for the difficulties to investigate the impact of resulting cell plasticity on tumor development, and justifies the challenge to prevent tumor recurrence. The emerging concept of cell plasticity and reciprocity (to change the phenotype by processing signals from the environment) throws more light on the actual complexity of tumor heterogeneity than can be expected solely from a unidirectional, classical cancer stem cell (CSC) model. To date, it remains widely unclear to what extent cell plasticity impacts tumor development, and it is difficult to assess by current methods. As a high tumor plasticity is likely to predict a poor outcome for patients, the future therapeutic challenge will be the development of personalized treatment strategies to predict and finally prevent cell plasticity in patients.

show abstract

Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth

Abstract: Neuropilin 1 mediates anti-tumor control by promoting regulatory T cell infiltration.

Cited by 212 publications

References 56 publications

CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful

CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful

Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma

Tumor cell plasticity: the challenge to catch a moving target

Contact Info

Product

Resources

About